President and Chief Executive OfficerDr. Spigelman is the President and Chief Executive Officer of the Global Alliance for TB Drug Development (TB Alliance), and a Member of its Board of Directors. Prior to being appointed President and CEO in 2009, Dr. Spigelman served for five and a half years as the Director of Research & Development at TB Alliance. He was instrumental in forging key organizational partnerships and building the pipeline of TB drug candidates. Notably, Dr. Spigelman was a leader in developing a regimen-based paradigm of TB drug development – a faster and more efficient approach, which is emerging as the gold standard within the TB drug research field.
Dr. Spigelman spent a decade managing drug R&D at Knoll Pharmaceuticals (a division of BASF Pharma) prior to joining TB Alliance. As Vice President of R&D at Knoll for eight years, Dr. Spigelman supervised all R&D activities from basic discovery to regulatory approval and Medical Affairs. He established global R&D processes as part of Knoll's senior R&D management team, oversaw a marked increase in US regulatory filings and approvals, and supervised joint R&D programs with multiple other pharmaceutical companies.
Dr. Spigelman received his undergraduate degree from Brown University and his medical degree from the Mt. Sinai School of Medicine where he specialized in Internal medicine, Neoplastic Diseases and Preventive Medicine. Dr. Spigelman holds board certifications from the American Board of Internal Medicine, the American Board's Subspecialty Board of Medical Oncology, and the American Board of Preventive Medicine and was the recipient of the American Cancer Society Clinical Oncology Career Development Award (1985-1988).
Presently, Dr. Spigelman is Co-Chair of the Working Group on New Drugs of the WHO Stop TB Partnership, and is a member of the Governing Board of the Tres Cantos Open Lab, GlaxoSmithKline.
Senior Vice President, External AffairsWillo Brock joined TB Alliance in 2014. As the Senior Vice President of External Affairs he is responsible for providing strategic leadership to the TB Alliance's fundraising, advocacy and policy, and community and stakeholder engagement work. Prior to joining TB Alliance, Mr. Brock worked for large international development organizations like WWF and Habitat for Humanity. His passion is bringing together people, for profit organisations, governments and civil society to tackle global issues of insecurity and inequality and develop effective programs giving people opportunities for growth and development.
Mr. Brock started his career working for the Netherlands Ministry of Development in Pakistan and continued working for MDF Training & Consultancy gaining over ten years of management consultancy, training, coaching and project management experience focused on non-profit clients. He worked in over 90 countries globally.
Mr. Brock received his Masters in Business Administration from the Erasmus University in Rotterdam.
Daniel E. Everitt
Vice President and Senior Medical OfficerDr. Everitt serves as Senior Medical Officer and works with the clinical development of products in the TB Alliance portfolio. Prior to joining the TB Alliance, he spent 10 years in Johnson & Johnson’s pharmaceutical sector. There, Dr. Everitt served in various roles, including as Vice President and Global Head of Clinical Pharmacology and Experimental Medicine at Johnson & Johnson Pharmaceutical Research and Development, and as Vice President of Safety Governance. Before working at Johnson & Johnson, Dr. Everitt spent 10 years in clinical research and development at SmithKline Beecham Pharmaceuticals. For six years, he was an Investigator in the Clinical Pharmacology Research Unit based at the University of Pennsylvania, and subsequently led Phase 2-4 development projects based in Harlow, United Kingdom, in the areas of neurosciences and anti-infectives.
Dr. Everitt gained his undergraduate degree from Duke University and his medical degree from Harvard Medical School. After an Internal Medicine residency at the Massachusetts General Hospital, he was a Fellow at Harvard in Geriatric Medicine and Clinical Epidemiology. Dr. Everitt is Board Certified in Internal Medicine, Geriatric Medicine and Clinical Pharmacology. He served on the faculty of departments of medicine at Harvard Medical School and at the University of Pennsylvania. In 2011, Dr. Everitt completed training and received a Diploma in Tropical Medicine and Hygiene from the London School of Hygiene and Tropical Medicine. Just prior to joining the TB Alliance, Dr. Everitt spent several months as a volunteer physician working in mission hospitals in Kenya. He is an author or co-author of 50 publications in peer-reviewed journals in the fields of Clinical Pharmacology and Pharmacoepidemiology.
Chief Scientific OfficerAs Chief Scientific Officer for the TB Alliance, Dr. Nader Fotouhi guides and oversees the organization’s research and preclinical development activities.
Dr. Fotouhi has 24 years of experience in the pharmaceutical industry, with significant research and early development expertise in a variety of therapeutic areas. Prior to joining the TB Alliance, Dr. Fotouhi held various leadership positions at Hoffmann-La Roche, including the head of the Discovery Chemistry group at the Nutley New Jersey site, the global head of Discovery Technologies, and served as the Nutley New Jersey Pharma Research and Early Development Site Leader.
Dr. Fotouhi holds a Ph.D. and Post Doctoral fellowship in Organic Chemistry from the Massachusetts Institute of Technology. Dr. Fotouhi has authored or co-authored more than 50 articles and presentations and holds 20 patents.
Senior Vice President, Market Access
Sandeep Juneja joined the TB Alliance in May 2018. As Senior Vice President of Market Access, he is responsible for leading the TB Alliance’s work in the design and implementation of market interventions and access strategies for rapid adoption and uptake of new TB regimens globally and in countries most affected with tuberculosis.
Mr. Juneja is passionate about shortening the gap between R&D and market availability of novel medicines, especially in developing countries. Prior to joining TB Alliance, Mr. Juneja worked as the head of business development at the Medicines Patent Pool, Geneva where he forged alliances with pharmaceutical industry, research institutes and other public health stakeholders to increase access to TB, HIV, and HCV medicines. Previously, he spent 17 years in the pharmaceutical industry in diverse roles including marketing, M&A, investor relations and was responsible for building an HIV and Malaria franchise in developing countries that resulted in access to HIV medicines in 60+ countries and development of an NCE for Malaria. He has served on several committees and panels related to Access to Medicines, such as the Advisory Board of the Medicines4All Institute, Steering Committee on Universal Access, Global Fund Procurement Advisory Panel, and Global Fund Market Dynamics Advisory Group.
An engineer by training, Mr. Juneja has a bachelor’s degree in technology from the Indian Institute of Technology and holds an MBA in International Business from the Indian Institute of Foreign Trade.
Robert C. Lorette
Senior Vice President, Business DevelopmentRobert C. Lorette, Esq. is Senior Vice President of Business Development for the TB Alliance. In this role,
Mr. Lorette helps lead the TB Alliance’s efforts to establish agreements and strategic alliances within the context of the product development partnership (PDP) business model, and thus play an integral role in achieving the portfolio development and related resource mobilization goals of the TB Alliance.
Before joining the TB Alliance, Mr. Lorette founded and was President and CEO of Boston Life Science Advisors, a corporate development consulting firm dedicated to serving biotech, medical device and other life science organizations. He also co-founded and served as Managing Director of Transform Ventures LLC, a firm that brings capital, executive leadership, and engineering and manufacturing resources together to rapidly advance medical device technologies to a significant value inflection point.
Before founding these two companies, Mr. Lorette served as Chief Business Officer and Senior Vice President of Dynogen Pharmaceuticals, Inc., a clinical-stage drug development company focusing on gastrointestinal and genitourinary disorders. Earlier in his career, Mr. Lorette served in various management, corporate development, and legal roles for organizations such as Boston Healthcare Associates, Inc., UroMed Corporation, and Bausch & Lomb Incorporated.
Mr. Lorette received his law degree from Syracuse University College of Law and is admitted to practice law in Massachusetts, Connecticut, and New York. Additional accreditations include a Masters in Public Administration from the Maxwell School of Syracuse University and a Bachelor’s degree in economics from the College of the Holy Cross. Mr. Lorette also attended the Program for Management Development at the Harvard Business School.
Senior Vice President, Research and DevelopmentAs Senior Vice President, Research and Development for the TB Alliance, Dr. Carl Mendel guides and oversees the organization’s research and development activities.
Dr. Mendel has more than 15 years of experience in the pharmaceutical industry, with significant research and development expertise in a variety of therapeutic areas, especially in early- and late-stage clinical development. Prior to his position with the TB Alliance, Dr. Mendel most recently served as Chief Medical Officer at Synvista Therapeutics. Prior, Dr. Mendel served in roles of increasing responsibility at Merck and Co., Knoll Pharmaceuticals (a division of BASF Pharma), Aventis Pharmaceuticals, and Sanofi-Aventis. During his career, he has contributed to the successful approvals of numerous pharmaceutical products that have been launched around the world.
Dr. Mendel holds a B.A. degree from Columbia University and an M.D. degree from the University of California, San Diego. He is board certified in Internal Medicine and in Endocrinology and Metabolism. Before joining the pharmaceutical industry, he was Assistant Professor of Medicine at the University of California, San Francisco. Dr. Mendel has authored or co-authored more than 50 articles in leading scientific journals.
Chief Administrative OfficerColleen Pero is Chief Administrative Officer for the Global Alliance for TB Drug Development.
In this role, she ensures operating effectiveness and management for the organization, and has specific oversight for cross-cutting strategies such as the TB Alliance pediatric initiative. Ms. Pero also serves as management liaison to the Board of Directors and corporate secretary. Additionally, Ms. Pero oversees internal operations, contracts administration, human resources, and information technology, among other areas, and is a member of the Senior Management Team.
An accomplished health care executive, Ms. Pero has a diverse professional background that includes over twenty years in the healthcare sector in both for-profit and not-for-profit environments. Before joining the TB Alliance, Ms. Pero was Senior Vice President, Corporate Administration at $2B specialty pharmaceutical and healthcare company Endo, where she built organizational capabilities to enable rapid growth, and participated in six-fold expansion of the market capitalization over five years. As a member of the executive team, Ms. Pero contributed to the establishment and execution of corporate strategy for the business, and she had direct responsibility for a wide range of areas including organizational planning, information technology, communications, company affairs, procurement, human resources and organizational development.
Since 2005, Ms. Pero has served as a Trustee for Christiana Care Health System, a $1.5B integrated healthcare system. She serves on the Executive Compensation Committee, which is responsible for executive and physician compensation, leadership development, and succession planning. Ms. Pero holds an MA in Management and a Bachelor of Science degree.
Vice President, Program and Alliance Management
Dr. Kathleen Schostack is Vice President of Program and Alliance Management for the TB Alliance. In this role, Dr. Schostack applies project management principles to develop comprehensive, integrated plans and track execution to best assure successful completion and support decision-making. Dr. Schostack also leads alliances with pharmaceutical partners to facilitate joint planning and alignment on deliverables to achieve program goals.
Dr. Schostack has more than 25 years of experience in pharmaceutical development, from early through late stage, registration, launch, and post-approval. Prior to joining the TB Alliance, Dr. Schostack held leadership positions at Hoffmann-La Roche and Bayer HealthCare in CMC, Regulatory and Project Management in a variety of therapeutic areas with a focus on Oncology.
Dr. Schostack earned her Ph.D. and MS in Chemistry at Stevens Institute of Technology and a BS from Penn State University.
Rajneesh (Raj) Taneja
Vice President, Pharmaceutical Product DevelopmentRajneesh (Raj) Taneja joined TB Alliance in April 2013 as Senior Director, Pharmaceutical Product Development. His responsibilities include designing and developing drug products for supporting preclinical and clinical programs, pediatric product development, and formulating combination drug products for enhancing dose compliance. Prior to joining TB Alliance, Raj was working at Takeda pharmaceuticals as Director of Product Development. There, he supported the development of numerous compounds from early development through obtaining regulatory approval. Raj is also a licensed pharmacist and he has 9 years of clinical pharmacy experience at Johns Hopkins Hospital, Baltimore MD.
Raj received his undergraduate degree in Pharmacy from Delhi University, India and he earned his Ph.D. in Biopharmaceutics & Industrial Pharmacy from the University of Maryland at Baltimore, MD. He is also an office holder at American Association of Pharmaceutical scientists (AAPS)